Actavis buys Warner Chilcott for $8.1bn
Specialty pharmaco Actavis Inc. has acquired publicly traded Warner Chilcott PLC (generics) in a stock swap valued at $8.1bn, including the assumption of $3.4bn of debt. The combined company is expected to adopt the name Actavis PLC and will be led by the current Actavis team. WC shareholders will get 0.160 shares of Actavis (equal to $18.62, a 7% premium) for each share they own; WC investors will hold 23% of the new company, which will be located in Ireland and is expected to trade on the NYSE.
- Generic Drugs
- Topical Delivery
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com